Disc Medicine (IRON) Receives a Buy from LifeSci Capital

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Disc Medicine today and set a price target of $100.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Katkhuda is a 5-star analyst with an average return of 31.8% and a 55.75% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Disc Medicine, Vera Therapeutics, and Viridian Therapeutics.

In addition to LifeSci Capital, Disc Medicine also received a Buy from Truist Financial’s Danielle Brill in a report issued on February 17. However, on February 4, TipRanks – OpenAI reiterated a Hold rating on Disc Medicine (NASDAQ: IRON).

Based on Disc Medicine’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $62.32 million. In comparison, last year the company had a GAAP net loss of $26.6 million

Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRON in relation to earlier this year. Earlier this month, Jean M. Franchi, the CFO of IRON sold 4,075.00 shares for a total of $256,154.50.